[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71:209−249

doi: 10.3322/caac.21660
[2]

Zheng R, Sun K, Han B, Li L, Chen R, et al. 2026. Cancer incidence and mortality in China, 2024. Journal of the National Cancer Center 1–10

doi: 10.1016/j.jncc.2025.10.003
[3]

Xia C, Li H, Wu C, Chen W. 2026. Cancer burden and control in China: landscape, trends and challenges. Nature Reviews Clinical Oncology 23:694−711

doi: 10.1038/s41571-026-01165-8
[4]

Zeng H, Zheng R, Sun K, Zhou M, Wang S, et al. 2024. Cancer survival statistics in China 2019–2021: a multicenter, population-based study. Journal of the National Cancer Center 4:203–213

doi: 10.1016/j.jncc.2024.06.005
[5]

Liu X, Li X, Yang F. 2022. Pattern of recurrence and metastasis after radical resection of non-small cell lung cancer. Chinese Journal of Lung Cancer 25:26−33 (in Chinese)

doi: 10.3779/j.issn.1009-3419.2021.102.50
[6]

Zeng H, Ran X, An L, Zheng R, Zhang S, et al. 2021. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. The Lancet Public Health 6:e877−e887

doi: 10.1016/S2468-2667(21)00157-2
[7]

Reuss JE, Bazhenova L, Ismaila N, Abu Rous F, Ahluwalia A, et al. 2026. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.0. Journal of Clinical Oncology 44:e56−e88

doi: 10.1200/JCO-25-02825
[8]

Verberkt CA, Billingy NE, Becker-Commissaris A, van den Hurk CJG, de Heij AH, et al. 2026. Distinct trajectories of symptom burden development in patients with stage IV cancer. Journal of Pain and Symptom Management 71:649−658.e2

doi: 10.1016/j.jpainsymman.2026.01.022
[9]

Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, et al. 2024. Osimertinib in patients with treatment-naive EGFR-mutant non-small cell lung cancer: overall survival, post-progression management and budget impact analysis in real-world. The Oncologist 29:596−608

doi: 10.1093/oncolo/oyae043
[10]

Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, et al. 2024. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 22:249−274

doi: 10.6004/jnccn.2204.0023
[11]

Li Y, Wang Q, Liu C, Hu X. 2023. Symptom clusters and their impact on quality of life among Chinese patients with lung cancer: a cross-sectional study. European Journal of Oncology Nursing 67:102465

doi: 10.1016/j.ejon.2023.102465
[12]

Takemura N, Cheung DST, Fong DYT, Ho MH, Lin CC. 2023. Relationship between cortisol rhythm and psychoneurological symptom cluster in patients with advanced lung cancer. Cancer Nursing 47:239−245

doi: 10.1097/NCC.0000000000001268
[13]

Ju X, Bai J, She Y, Zheng R, Xu X, et al. 2023. Symptom cluster trajectories and sentinel symptoms during the first cycle of chemotherapy in patients with lung cancer. European Journal of Oncology Nursing 63:102282

doi: 10.1016/j.ejon.2023.102282
[14]

Li N, Wu J, Zhou J, Wu C, Dong L, et al. 2021. Symptom clusters change over time in patients with lung cancer during perichemotherapy. Cancer Nursing 44:272−280

doi: 10.1097/NCC.0000000000000787
[15]

Wong ML, Cooper BA, Paul SM, Levine JD, Conley YP, et al. 2017. Differences in symptom clusters identified using ratings of symptom occurrence vs severity in lung cancer patients receiving chemotherapy. Journal of Pain and Symptom Management 54:194−203

doi: 10.1016/j.jpainsymman.2017.04.005
[16]

Dodd MJ, Miaskowski C, Paul SM. 2001. Symptom clusters and their effect on the functional status of patients with cancer. Oncology Nursing Forum 28:465−470

[17]

Miaskowski C, Dodd M, Lee K. 2004. Symptom clusters: the new frontier in symptom management research. Journal of the National Cancer Institute Monographs 32:17−21

doi: 10.1093/jncimonographs/lgh023
[18]

Kim HJ, McGuire DB, Tulman L, Barsevick AM. 2005. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nursing 28:271−282

doi: 10.1097/00002820-200507000-00005
[19]

Choi YY, Akter J, Lee J. 2024. Symptom clusters among lung cancer patients: a scoping review. Korean Journal of Adult Nursing 36:271−297

doi: 10.7475/kjan.2024.36.4.271
[20]

Shao X, Wang N, Tang K, Wang K, Tan Z, et al. 2025. Network analysis used to investigate the symptoms of cancer patients during chemotherapy: a scoping review. Discover Oncology 16:1011

doi: 10.1007/s12672-025-02837-0
[21]

Li Y, Hu X. 2025. Symptom clusters and core symptoms of Chinese patients with lung cancer: a cross-sectional study. The Lancet Regional Health - Western Pacific 55:101358

doi: 10.1016/j.lanwpc.2024.101358
[22]

Bulto LN, Davies E, Kelly J, Hendriks JM. 2024. Patient journey mapping: emerging methods for understanding and improving patient experiences of health systems and services. European Journal of Cardiovascular Nursing 23:429−433

doi: 10.1093/eurjcn/zvae012
[23]

Tong A, Sainsbury P, Craig J. 2007. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care 19:349−357

doi: 10.1093/intqhc/mzm042
[24]

LaDonna KA, Artino AR Jr, Balmer DF. 2021. Beyond the guise of saturation: rigor and qualitative interview data. Journal of Graduate Medical Education 13:607−611

doi: 10.4300/JGME-D-21-00752.1
[25]

Colaizzi PF. 1978. Psychological research as the phenomenologist views it. In Existential-Phenomenological Alternatives for Psychology, eds. Valle RS, King M. New York: Oxford University Press. pp. 48−71 https://ci.nii.ac.jp/naid/10028127253

[26]

Zhang F, Wang Y, Xiao Y, Li J, Liu Y, et al. 2026. Journey mapping of the patient experience from diagnosis to end of life in lung cancer: a qualitative meta-synthesis. Seminars in Oncology Nursing 42:152260

doi: 10.1016/j.soncn.2026.152260
[27]

Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, et al. 2001. Advancing the science of symptom management. Journal of Advanced Nursing 33:668−676

doi: 10.1046/j.1365-2648.2001.01697.x
[28]

Jia R, Zou J, Hu H, Wang X, Zheng Y, et al. 2025. Patient-reported outcomes with first-line immunotherapy-based combination treatment for advanced lung cancer: a prospective, multicenter, observational study. Thoracic Cancer 16:e70155

doi: 10.1111/1759-7714.70155
[29]

Petrasso C, Bayly J, Fettes L, Ashford S, Maddocks M. 2025. Interplay between mobility, social participation, and symptom burden in advanced lung cancer. Supportive Care in Cancer 34:42

doi: 10.1007/s00520-025-10269-3
[30]

Liu T, He J, Wang Y, Yang Y, Zhang L, et al. 2025. Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): a randomized, double-blind, phase 3 trial. Lung Cancer 200:108108

doi: 10.1016/j.lungcan.2025.108108
[31]

Yan Z, Xiao LD, Guo X, Hu Y, Wang N, et al. 2025. The impact of social support and social constraints on sleep disturbances in patients with lung cancer undergoing chemotherapy: serial mediators of sleep cognition and anxiety-depression. Asia-Pacific Journal of Oncology Nursing 12:100740

doi: 10.1016/j.apjon.2025.100740
[32]

Zhou Z, Yang Y, Sun J, Dong Y, Zhu M, et al. 2024. Heterogeneity of pain-fatigue-sleep disturbance symptom clusters in lung cancer patients after chemotherapy: a latent profile analysis. Supportive Care in Cancer 32:821

doi: 10.1007/s00520-024-09032-x
[33]

Crawford J, Herndon D, Gmitter K, Weiss J. 2024. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncology 20:1515−1530

doi: 10.2217/fon-2023-0513
[34]

Duan L, Cui H, Zhang W, Wu S. 2022. Symptoms and experiences of frailty in lung cancer patients with chemotherapy: a mixed-method approach. Frontiers in Oncology 12:1019006

doi: 10.3389/fonc.2022.1019006
[35]

Mao D, Luo Y, Zhang L, Liu S, Zhu B, et al. 2025. Trajectories of fatigue-pain-sleep disturbance symptom cluster in patients with lung cancer undergoing chemotherapy and its predictive factors: latent class growth model. Supportive Care in Cancer 33:1155

doi: 10.1007/s00520-025-10137-0
[36]

Defty J, Wagland R, Turnbull J, Richardson A. 2025. Symptom appraisal and help-seeking for complications of cancer and its treatment: a systematic review and qualitative synthesis. BMJ Supportive & Palliative Care Published Online First

doi: 10.1136/spcare-2025-005477
[37]

Cassim S, Chepulis L, Keenan R, Kidd J, Firth M, et al. 2019. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer 19:25

doi: 10.1186/s12885-018-5169-9
[38]

Zhang J, IJzerman MJ, Oberoi J, Karnchanachari N, Bergin RJ, et al. 2022. Time to diagnosis and treatment of lung cancer: a systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer 166:27−39

doi: 10.1016/j.lungcan.2022.01.015
[39]

Rowntree RA, Hosseinzadeh H. 2022. Lung cancer and self-management interventions: a systematic review of randomised controlled trials. International Journal of Environmental Research and Public Health 19:536

doi: 10.3390/ijerph19010536